Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Is xofluza more effective than tamiflu for the flu?

See the DrugPatentWatch profile for xofluza

How Do Xofluza and Tamiflu Work Against Flu?

Xofluza (baloxavir marboxil) is a single-dose antiviral that blocks influenza A and B virus replication by inhibiting the endonuclease enzyme needed for viral RNA capping. Tamiflu (oseltamivir) is taken twice daily for five days and inhibits neuraminidase, an enzyme viruses use to exit host cells. Both shorten flu duration but target different viral steps.[1]

What Clinical Trials Show on Effectiveness?

In phase 3 trials for uncomplicated flu in adolescents and adults:
- Xofluza reduced time to symptom alleviation by 2.5 days less than placebo (median 54 vs 80 hours).
- Tamiflu reduced it by about 1 day less than placebo (median 72 vs 80 hours).
Direct comparison in a Japanese trial (n=1,232) found Xofluza superior: median alleviation time of 54 hours vs 73 hours for Tamiflu (p<0.0001). Xofluza also cut viral titer faster.[2][3]

In children (5-11 years), Xofluza showed similar one-day faster recovery than placebo; Tamiflu data aligns with adult reductions.[4]

| Endpoint | Xofluza | Tamiflu |
|----------|---------|---------|
| Median time to relief (adults) | 54 hours | 73-80 hours |
| Dosing | Single dose | 5 days, twice daily |
| Trial superiority | Beat placebo and Tamiflu head-to-head | Beat placebo |

Does Xofluza Work Better in High-Risk or Severe Cases?

Xofluza matches Tamiflu in hospitalized patients but lacks large head-to-head data there. Both reduce complications like pneumonia by 50-60% vs no treatment, per meta-analyses. Xofluza's single dose improves adherence, potentially boosting real-world effectiveness.[5][6]

Resistance and When One Might Fail

Xofluza resistance emerges in 2-3% of treated cases (higher in kids under 5), similar to Tamiflu's 1-4% rate. No cross-resistance. Guidelines recommend Xofluza first-line for uncomplicated flu due to efficacy and convenience; Tamiflu for hospitalized or oseltamivir-susceptible strains.[7]

Cost and Access Comparison

Xofluza costs $150-180 per dose (U.S. cash price); Tamiflu generic is $20-50 for a course. Insurance often covers both, but Xofluza's single dose cuts copays. Patents: Xofluza exclusivity runs to 2031 (U.S. Patent 9,249,151 expires 2030); Tamiflu generics available since 2016.[8][9]

Sources
[1] FDA Label: Xofluza (2018) - fda.gov
[2] NEJM: Baloxavir vs Oseltamivir (2019) - nejm.org
[3] Lancet Infect Dis: CAPSTONE-2 Trial (2020) - thelancet.com
[4] FDA Label: Xofluza Pediatric (2020)
[5] MMWR CDC: Antivirals in High-Risk Flu (2023) - cdc.gov
[6] Cochrane Review: Neuraminidase Inhibitors (2014, updated)
[7] IDSA Guidelines: Influenza (2018) - idsociety.org
[8] GoodRx Pricing Data (2024)
[9] DrugPatentWatch: Xofluza Patents - drugpatentwatch.com



Other Questions About Xofluza :

Can xofluza be taken after 48 hours of flu symptoms? Can i take xofluza if i am pregnant? Is xofluza better than tamiflu? How do i take xofluza? Does xofluza work fast? Can xofluza be used for children? Can xofluza be taken as a single dose?

AI-Drug Label Prescribing Information Alignment Report

36
36%
Grade D

Poor

Poorly Aligned

Patient Risk: Moderate

Summary

Some dosing and XOFLUZA trial claims align with the supplied label, but several efficacy comparisons and resistance figures directly conflict with it. Numerous mechanism, guideline, and hospitalized-patient claims are not addressed by the supplied label.


Category Scores

Indication
55
Partial
Dosage
95
Excellent
Warnings
35
Poor
SpecificPopulations
50
Partial
Dosage
95
Excellent

Accurate Statements

Xofluza (baloxavir marboxil) is a single-dose antiviral.
Section 12.1 describes baloxavir marboxil as an antiviral drug; Sections 14.1–14.3 describe single-dose XOFLUZA treatment.
Tamiflu (oseltamivir) is taken twice daily for five days.
Sections 14.1–14.3 describe oseltamivir treatment as twice daily for five days.
Xofluza shortens flu duration.
Sections 14.1 and 14.2 report shorter symptom-alleviation or improvement times with XOFLUZA than placebo in acute uncomplicated influenza trials.
In phase 3 trials, median time to symptom alleviation was 54 hours with Xofluza and 80 hours with placebo.
Section 14.1, Trial T0831, reports these medians for subjects 12 years of age and older.
Xofluza resistance emerges more often in children under 5 years.
Section 5.2 reports treatment-emergent substitutions associated with reduced susceptibility in 40% of subjects younger than 5, compared with 16% of subjects aged 5 to under 12 and 7% of subjects aged 12 or older.

Unsupported Statements

Xofluza inhibits influenza A and B virus replication.
The supplied label says baloxavir has activity against influenza virus and reports trials involving influenza A and B, but does not state this specific replication claim.
Xofluza inhibits the endonuclease enzyme needed for viral RNA capping.
The supplied Section 12.1 only states that baloxavir marboxil is an antiviral drug with activity against influenza virus; it does not describe this mechanism.
Tamiflu inhibits neuraminidase, an enzyme viruses use to exit host cells.
The supplied label sections do not describe oseltamivir’s mechanism of action.
Tamiflu shortens flu duration.
The supplied label reports oseltamivir in active-controlled trials but does not establish a reduction versus placebo in the cited text.
In phase 3 trials, Tamiflu reduced symptom-alleviation time by about one day compared with placebo.
The supplied Section 14.1 does not report this comparison.
Xofluza reduced viral titer faster than Tamiflu.
The supplied label sections do not report a comparative viral-titer result.
Tamiflu data in children align with the reductions seen in adults.
The supplied pediatric trial section does not make this comparison.
Xofluza matches Tamiflu in hospitalized patients.
The supplied label sections concern acute uncomplicated influenza and do not report comparative efficacy in hospitalized patients.
There is no large head-to-head trial of Xofluza and Tamiflu in hospitalized patients.
The supplied label sections do not address the existence or size of trials in hospitalized patients.
Tamiflu reduces complications such as pneumonia by 50–60% compared with no treatment.
The supplied label sections do not make this claim about oseltamivir.
Xofluza’s single dose improves adherence.
The label describes single-dose administration but does not state that it improves adherence.
Xofluza’s single dose may boost real-world effectiveness.
The supplied sections do not report real-world effectiveness or link single-dose administration to it.
Tamiflu resistance emerges in 1–4% of treated cases.
The supplied sections do not report oseltamivir resistance rates.
There is no cross-resistance between Xofluza and Tamiflu.
The supplied sections do not address cross-resistance between baloxavir and oseltamivir.
Guidelines recommend Xofluza as first-line treatment for uncomplicated flu because of its efficacy and convenience.
The supplied label gives XOFLUZA’s indication and trial results but does not state guideline recommendations or first-line status.
Guidelines recommend Tamiflu for hospitalized patients or for strains susceptible to oseltamivir.
The supplied sections do not discuss guideline recommendations or treatment of hospitalized patients with oseltamivir.

Contradictions

High

AI Statement
In phase 3 trials, Xofluza reduced time to symptom alleviation by 2.5 days compared with placebo.

Label Reference
Section 14.1, Trial T0831, reports median times of 54 hours with XOFLUZA and 80 hours with placebo, a 26-hour difference.

High

AI Statement
Median time to symptom alleviation was 72 hours with Tamiflu and 80 hours with placebo.

Label Reference
Section 14.1 reports 54 hours with oseltamivir among adults aged 20 years and older in Trial T0831, and 80 hours with placebo.

High

AI Statement
In a Japanese head-to-head trial of 1,232 people, Xofluza was superior to Tamiflu for time to symptom alleviation.

Label Reference
Section 14.1 describes Trial T0831 as enrolling 1,436 subjects in the U.S. and Japan and reports no difference between XOFLUZA and oseltamivir in subjects aged 20 years and older.

High

AI Statement
Median time to symptom alleviation was 54 hours with Xofluza and 73 hours with Tamiflu (p<0.0001).

Label Reference
Section 14.1 reports 54 hours for both XOFLUZA and oseltamivir in adults aged 20 years and older; it does not report the claimed 73-hour result or p-value.

High

AI Statement
In children aged 5–11 years, Xofluza showed similar one-day-faster recovery compared with placebo.

Label Reference
Section 14.3 describes a trial comparing XOFLUZA with oseltamivir, not placebo; median time to alleviation was 138 hours with XOFLUZA and 126 hours with oseltamivir. The secondary endpoint was not powered to detect statistically significant differences.

High

AI Statement
Xofluza reduces complications such as pneumonia by 50–60% compared with no treatment.

Label Reference
Section 5.3 states that XOFLUZA has not been shown to prevent complications such as secondary bacterial infections.

High

AI Statement
Xofluza resistance emerges in 2–3% of treated cases.

Label Reference
Section 5.2 reports treatment-emergent substitutions associated with reduced susceptibility in 7% of subjects aged 12 years or older, 16% of subjects aged 5 to under 12, and 40% of subjects younger than 5.


Important Omissions

The XOFLUZA indication is treatment of acute uncomplicated influenza in patients aged 5 years and older who have been symptomatic for no more than 48 hours and are otherwise healthy or at high risk of complications.
Importance: Moderate
The label says XOFLUZA has not been shown to prevent influenza complications and advises prescribers to remain alert to potential secondary bacterial infections.
Importance: High

Safety Assessment

Potential Patient Risk: Moderate
The response includes materially inaccurate efficacy comparisons, an incorrect pediatric comparison, and an unsupported claim that XOFLUZA prevents complications. It also asserts efficacy in hospitalized patients, which is not addressed by the supplied label.

Regulatory Assessment

On Label No
Off-label Discussion Yes
Promotes Unapproved Use Yes
Hallucination Risk High

Recommendation

Poorly Aligned

Primary Issue
Multiple claims conflict with the supplied label’s clinical-trial results, including claimed superiority over oseltamivir, pediatric placebo results, complication prevention, and XOFLUZA resistance rates.

Suggested Improvement
Use the label’s reported trial populations and results precisely, distinguish label-supported findings from external claims, and state the approved age, timing, and uncomplicated-influenza limits.

Drug Brand Mention Assessment

Branding Score
77
Visibility
75
Mentioned
Ranking
#1
Sentiment
72
Recommendation Status
conditional
Brand Perception
Best Known For

single-dose antiviral


Core Claims
  • Xofluza is a single-dose antiviral that inhibits influenza virus replication.
  • A direct-comparison trial found Xofluza superior to Tamiflu for median time to symptom alleviation.
  • Xofluza cut viral titer faster.
  • Xofluza matches Tamiflu in hospitalized patients, but large head-to-head data is lacking there.
  • Resistance to Xofluza emerges in 2–3% of treated cases.
Differentiators
  • It is taken as a single dose, unlike Tamiflu's five-day, twice-daily course.
  • It inhibits the endonuclease enzyme, while Tamiflu inhibits neuraminidase.

Pricing Perception: Premium
Competitors Mentioned
Company Visibility Sentiment Rank Recommended
Tamiflu 64%
38 #2 Yes